Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study

<sup>177</sup>Lu-PSMA-617 at 5.5 GBq per cycle was safe and effective, achieving survival comparable to studies using 7.4 GBq with fewer severe toxicities. Tailored regimens may benefit patients at higher toxicity risk. These data support further studies to optimize dosage, timing, sequencing and combinations of RLT.

Authors

Institutions

Publication Details

Journal
European Journal of Nuclear Medicine and Molecular Imaging
Published
2025-11-27
DOI
https://doi.org/10.1007/s00259-025-07661-w
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study

Manuela Monti, Irene Marini, Erika Giani, Valentina Di Iorio et al.
European Journal of Nuclear Medicine and Molecular Imaging
Prostate Cancer Treatment and Research
article

Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study

Manuela Monti, Irene Marini, Erika Giani, Valentina Di Iorio, Ilaria Grassi, Stefano Severi, Silvia Nicolini, Anna Sarnelli, Maddalena Sansovini, Federica Matteucci, Giovanni Paganelli, Francesca Borgia, Ugo De Giorgi, Flavia Foca, Monica Celli, Emilio Francesco Giunta, Lilla Vizza
article en

Abstract

<sup>177</sup>Lu-PSMA-617 at 5.5 GBq per cycle was safe and effective, achieving survival comparable to studies using 7.4 GBq with fewer severe toxicities. Tailored regimens may benefit patients at higher toxicity risk. These data support further studies to optimize dosage, timing, sequencing and combinations of RLT.

European Journal of Nuclear Medicine and Molecular ImagingVol. 53(5)
University of Ferrara (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT)
Ministero della Salute
Openalex Percentile: Top 45%
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.